Brief: Lantheus Receives FDA Tentative Approval For Lutetium Lu 177 Dotatate (Pnt2003), Radioequivalent To Lutathera®
02/03/2026 13:31
March 2 (Reuters) - Lantheus Holdings Inc LNTH.O: LANTHEUS RECEIVES FDA TENTATIVE APPROVAL FOR LUTETIUM LU 177 DOTATATE (PNT2003), RADIOEQUIVALENT TO LUTATHERA® Source text: ID:nGNX9nwSnk Further company coverage: LNTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsBrief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
Lantheus falls after report it is considering potential $7 billion sale